Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | CuttingEdgeInfo Reports | The Changing MSL Role: Proving Value Through Performance Measurement (PH115)

The Changing MSL Role: Proving Value Through Performance Measurement (PH115)

Revolutionize your MSL teams to help drive bottom-line results:

In the past, medical science liaisons (MSLs) served a traditional role as scientific support to sales. But market realities, including fewer drug approvals and increasing regulatory demands, have led companies to put a premium on building productive relationships with key opinion leaders and supporting company objectives through medical education.

Today, MSLs are evolving into a more independent, highly strategic function. Innovative companies rely heavily on MSLs’ scientific expertise to support educational, training, research and clinical initiatives. MSLs are emerging as solutions-driven knowledge workers and as peer-level conduits to leaders in the medical community. Through MSLs, thought leaders gain access to company decision-makers in areas such as clinical development, medical affairs, and marketing.

MSLs are in a pivotal position to influence corporate strategy. Forward-thinking organizations that recognize MSLs’ shift in responsibilities and leverage the function’s scientific expertise can adapt their strategies to measure MSL performance. They are ultimately better poised for success.

This study covers these key aspects of MSL programs:

* Structure, Budgets and Staffing: This section details companies’ structuring and alignment strategies, investment levels, and headcounts.

* MSL Qualifications and Performance Measurement: This section explores the increasing educational and clinical experience required for MSL candidates. It includes compensation data. It also examines ways in which companies gauge MSL effectiveness and contributions to company goals.

* Field Force Strategies and Communication: This section outlines MSL activities and responsibilities. It also examines the connections between sales forces and MSLs in the new compliance environment and provides recommendations for integrated communications between those groups.

Companies Included in Report:

Abbott Laboratories

Allergan

Amgen

Angiotech

Baxter Healthcare

Bayer Schering

Bristol-Myers Squibb

Cangene

CORONIS Research

Cytogen

Enzon

Janssen-Cilag

Johnson & Johnson

King Pharmaceuticals

Medtronic

Myogen

Novartis

Novo Nordisk

Organon

OrthoNeutrogena

Pfizer

Sanofi-Aventis

Schering-Plough

Solvay

Valeritas

Wyeth

A small medical device company

A small pharmaceutical company

Published 2008

203 Pages

300+ Metrics

150+ Charts and Diagrams
Table of Contents
Price: $7,695.00 / €5,147.96

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions